Mostrar el registro sencillo del ítem
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
dc.contributor.author | Mangia, A. | |
dc.contributor.author | Milligan, S. | |
dc.contributor.author | Khalili, M. | |
dc.contributor.author | Fagiuoli, S. | |
dc.contributor.author | Shafran, S. D. | |
dc.contributor.author | Carrat, F. | |
dc.contributor.author | Ouzan, D. | |
dc.contributor.author | Papatheodoridis, G. | |
dc.contributor.author | Ramji, A. | |
dc.contributor.author | Borgia, S. M. | |
dc.contributor.author | Wedemeyer, H. | |
dc.contributor.author | Losappio, R. | |
dc.contributor.author | Perez-Hernandez, F. | |
dc.contributor.author | Wick, N. | |
dc.contributor.author | Brown, R. S. | |
dc.contributor.author | Lampertico, P. | |
dc.contributor.author | Doucette, K. | |
dc.contributor.author | Ntalla, I. | |
dc.contributor.author | Ramroth, H. | |
dc.contributor.author | Mertens, M. | |
dc.contributor.author | Vanstraelen, K. | |
dc.contributor.author | Turnes Vázquez, Juan | |
dc.date.accessioned | 2022-03-23T08:54:20Z | |
dc.date.available | 2022-03-23T08:54:20Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32449966 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16360 | |
dc.description.abstract | BACKGROUND AND AIMS: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. METHODS: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. RESULTS: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P = .002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). CONCLUSIONS: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.mesh | Heterocyclic Compounds | * |
dc.subject.mesh | Drug Therapy | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Ribavirin | * |
dc.subject.mesh | Hepacivirus | * |
dc.subject.mesh | Genotype | * |
dc.subject.mesh | Carbamates | * |
dc.subject.mesh | Antiviral Agents | * |
dc.title | Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts | en |
dc.type | Journal Article | es |
dc.authorsophos | Mangia, A.;Milligan, S.;Khalili, M.;Fagiuoli, S.;Shafran, S. D.;Carrat, F.;Ouzan, D.;Papatheodoridis, G.;Ramji, A.;Borgia, S. M.;Wedemeyer, H.;Losappio, R.;Perez-Hernandez, F.;Wick, N.;Brown, R. S.;Lampertico, P.;Doucette, K.;Ntalla, I.;Ramroth, H.;Mertens, M.;Vanstraelen, K.;Turnes, J. | |
dc.identifier.doi | 10.1111/liv.14537 | |
dc.identifier.pmid | 32449966 | |
dc.identifier.sophos | 36601 | |
dc.issue.number | 8 | es |
dc.journal.title | LIVER INTERNATIONAL | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Dixestivo | es |
dc.page.initial | 1841 | es |
dc.page.final | 1852 | es |
dc.relation.publisherversion | https://air.unimi.it/retrieve/handle/2434/776962/1598458/liv.14537.pdf | es |
dc.rights.accessRights | openAccess | |
dc.subject.decs | resultado del tratamiento | * |
dc.subject.decs | ribavirina | * |
dc.subject.decs | antivíricos | * |
dc.subject.decs | carbamatos | * |
dc.subject.decs | genotipo | * |
dc.subject.decs | farmacoterapia | * |
dc.subject.decs | humanos | * |
dc.subject.decs | adulto | * |
dc.subject.decs | Hepacivirus | * |
dc.subject.decs | compuestos heterocíclicos | * |
dc.subject.keyword | CHUP | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 40 | es |